Parkinson DiseaseNCT04620863
TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE
A study testing t-DCS group in people with Parkinson Disease and Pisa Syndrome, run by IRCCS National Neurological Institute "C. Mondino" Foundation at 1 site in Italy.
Trial summary
Pisa Syndrome (PS) is a lateral trunk flexion frequently associated to Parkinson's disease (PD). The management of PS is still a challenge for the clinician, because it poorly responds to anti-parkinsonian drugs, and the improvement achieved with neurorehabilitation or botulinum toxin injections tends to fade in 6… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Parkinson Disease, Pisa Syndrome
- What is being tested?
- t-DCS group
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteItaly
- Study dates
- 15 Jan 2019to 15 Sep 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age between 18 and 80 years;
- Hoehn and Yahr stage between II and III;
- Mini-Mental State Examination score above 24;
- lateral trunk flexion of at least 10° at baseline.
Who cannot join
- history of major psychiatric or other neurological conditions;
- history of back surgery, tumors or infections of the spine, intradural or extradural hematoma, ankylosing spondylitis, spinal stenosis;
- history of idiopathic scoliosis;
- botulin toxin treatment in the previous year;
- any change in dose or regimen of the anti-parkinsonian therapy in the last month before enrolment.
- Thirty patients affected by Parkinson' Disease (PD) and Pisa Syndrome (PS) were consecutive enrolled among those attending the Neurorehabilitation Department of the IRCCS Mondino Foundation (Pavia, Italy). Idiopathic PD was diagnosed according to the Movement Disorders Society clinical diagnostic criteria for PD. Pisa syndrome was clinically diagnosed according to the following criteria:
Show all 10Show fewer
- a lateral flexion of the trunk with a homogenous angle between sacrum and spinous process of the 7th cervical vertebra;
- an ipsilateral axial rotation of the trunk around the sagittal axis, that leads to a higher and anterior position of the shoulder contralateral to the side of trunk deviation;
- the worsening of the postural disorder during standing position, sitting position and gait;
- the improvement of the postural disorder in supine position.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE: A RANDOMIZED CONTROLLED TRIAL
Pisa Syndrome (PS) is a lateral trunk flexion frequently associated to Parkinson's disease (PD). The management of PS is still a challenge for the clinician, because it poorly responds to anti-parkinsonian drugs, and the improvement achieved with neurorehabilitation or botulinum toxin injections tends to fade in 6 months or less. Transcranial direct current stimulation (t-DCS) is a non-invasive neuromodulation technique, with promising results in movement disorders. Aim of our study is to evaluate the role of bi-hemispheric t-DCS as add-on to neurorehabilitation in PS. Twenty-eight patients affected by PD and PS were managed with a 4-week hospital neurorehabilitation programme and randomized to: 1) t-DCS group: 5 daily sessions (20 minutes - 2 mA) with cathode over the primary motor cortex (M1) contralateral to PS, and anode over the M1 cortex ipsilateral to PS; or 2) sham group. Patients were tested with kinematic analysis of trunk movement in static and dynamic conditions, UPDRS-III, FIM, and VAS for lumbar pain rating at hospital admission (T0), at hospital discharge (end of neurorehabilitation - T1), and 6 months later (T2). At T0, the evaluations were completed by an EMG study of trunk muscles activation.
Read the detailed description
Axial disorders are frequent complications of Parkinson's Disease (PD) and they can lead to postural deformities and balance impairments. The most prevalent postural disorders of PD are represented by camptocormia, antecollis, scoliosis, and Pisa syndrome (PS).
The pathogenesis of these disorders has not yet been completely elucidated, and it is characterized by a complex interlacement between central and peripheral mechanisms.
The first report of PS dates back in 1972, when Ekobm described a case series of three patients who developed a lateral trunk flexion in close temporal relationship with neuroleptics assumption. The roster of drugs associated with an acute/subacute onset of PS is huge and constantly growing, and it includes: antidepressants (mirtazapine, sertraline), cholinesterase inhibitor (rivastigmine, galantamine, donepezil), neuroleptics (tiapride, clotiapine, clozapine, aipiprazole, butyrophenone, paliperidone, quetiapine), dopamine agonists, (pramipexolo, ropinirole, pergolide), lithium, valproic acid, and betahistine. Nonetheless, PS was described as well in patients with neurodegenerative disorders, and in particular in PD and parkinsonism without drugs exposure.
The prevalence of PS is around 8.3% (9.3% in women and 6.4% in men) when calculated in a psychogeriatric population, and it is 8 to 8.8% when populations of PD patients were considered.
Formal diagnostic criteria for PS are not available, indeed the diagnosis is based on the clinical features:
- presence of a lateral flexion of the trunk with a homogenous angle between sacrum and spinous process of the 7th cervical vertebra;
- association of an ipsilateral rotation of the trunk around the sagittal axis that leads to a higher and anterior position of the shoulder contralateral to the side of trunk deviation;
- the postural disorder worsens during standing position, sitting position and gait;
- the postural disorder improves in supine position;
- disregard of patients for the postural disorder.
The fluctuation of the postural alteration during static (supine position vs. upright standing position) and dynamic conditions appears to be crucial to differentiate PS from scoliosis.
A lateral trunk deviation of at least 10° is commonly accepted for the diagnosis, although higher or lower cut-offs were used in the past. According to the degree of the lateral trunk flexion, PS can be further divided in mild (less than 20°) or severe (more than 20°) phenotypes.
Patients with PD and PS showed some typical clinical and demographic features when compared to PD patients without postural alterations: they are older, PD is longer in duration, more severe and with a more pronounced asymmetry of motor symptoms. The parkinsonian symptoms involving the upper limbs as well as gait impairment are more severe in PD patients with PS. Moreover, they are characterized by a higher incidence of falls, arthrosis, osteoporosis, orthopedics diseases and pain, specifically lumbar and lower back pain, which is reported in up to 75% of patients with PD and PS.
The management of PS is still a challenge for the physician. PS poorly responds to antiparkinsonian drugs, although there aren't studies specifically designed to assess this topic.
Neurorehabilitation represents one of the fundamental approach to PD and to postural disorders in general, not only for the treatment of the motor symptoms itself but also to improve quality of life and autonomy in the activity of daily living.
The study was a randomized, double-blind, controlled trial aimed to assess the efficacy of five daily sessions of bi-hemispheric t-DCS in add-on to an in-hospital neurorehabilitation protocol in patients affected by PD and PS.
At hospital admission (T0 - baseline), all patients underwent complete neurological, general and functional examinations by a Neurologist with expertise in movement disorders and neurorehabilitation. Patients who fulfilled inclusion and exclusion criteria underwent a baseline kinematic analysis of trunk movement. Patients with at least 10° of lateral trunk flexion completed the baseline evaluations with a dynamic electromyographic (EMG) study of trunk muscles, and with administration of a set clinical scales for the evaluations of motor disability, functional independence, and lumbar pain.
After that, patients were randomly assigned to "t-DCS" or "sham" treatment, and they started the double-blind phase of the study. The 5-day t-DCS/sham treatment was delivered in 5 daily consecutive sessions, starting from the first Monday after hospital admission. In parallel to neuromodulation, all patients were treated with a standardized 4-week rehabilitation programme. The kinematic analysis of trunk movement as well as the administration of the set of questionnaires were repeated at the end of the 4-week rehabilitation programme (T1 - hospital discharge), and 6 months after discharge (T2).
The randomization was performed according to a block randomization method. A unique randomization list was generated before enrollment with the following parameters: 6 blocks; 6 patients per block (3 for t-DCS group, and 3 for sham group).
All the patients were treated with an optimized and individualized anti-parkinsonian therapy, which dose and regimen were kept stable during the overall study period. All the evaluations were performed in the morning, and always in an ON phase.
The specific and standardized in-hospital rehabilitation programme was focused on the rehabilitation of the trunk postural disorder. All patients were treated with 90-minute daily sessions, 6 days a week (Monday to Saturday) for four weeks.
Each session was structured as follow:
- 10 minutes of cardiovascular warm-up activities: intersegmental coordination exercises; exercises to release shoulder and pelvic girdle; pelvic anteversion and retroversion movements to improve diaphragmatic respiration (supine position); breathing exercises to promote expansion of the chest;
- 15 minutes of stretching exercises: exercises to stretch the muscles of the posterior kinematic chain; exercises to stretch the pectoralis muscles; exercises to stretch the ischio-cruralis muscles; assumption of the prone position, sitting on heels and stretching the arms out in front; the "bridge" exercise to stretch the muscles of the anterior abdominal wall, glutei, quadriceps and hamstring; exercises to stretch lumbar muscles (in the supine position, each knee, in turn, is brought to the chest);
- 15 minutes of strengthening exercises in a functional context: exercises to strengthen the dorsal muscles (arms extended and hands outstretched as though to take something); lateral bending (arms lying along the body and hands reaching down as though to pick up something); stretching using the wall bars;
- 20 minutes of gait training: overground gait training (forwards, backwards, and lateral); walking on the spot;
- 15 minutes of balance training: path with obstacles; balance exercises performed in order of difficulty (heel-to-toe walking, lateral walking crossing the legs, walking along a path on surfaces of different texture);
- 15 minutes of relaxation exercises: intersegmental coordination exercises; segmental passive mobilization (until maximum joint range of motion is reached); breathing exercises to promote expansion of the chest.
- Conditions
- Parkinson Disease, Pisa Syndrome
- Being tested
- t-DCS group, Sham group
- Keywords
- Parkinson Disease, Pisa Syndrome, Transcranial direct current stimulation
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
t-DCS groupOther
All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).
Sham groupOther
The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
| Study group | Role | What they receive |
|---|---|---|
| tDCS group | Experimental | Patients randomized to the experimental group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity delivered at anodal and cathodal levels. Receives: Other: t-DCS group |
| Sham Group | Sham comparator | The stimulation setting was exactly the same of the experimental group but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation. Receives: Other: Sham group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of Stat Tot (Stat Bend + Stat Flex)
Total postural alteration in the upright standing position (Stat Tot): lateral trunk inclination in the upright standing position (Stat Bend) plus anterior trunk flexion in the upright standing position (Stat Flex).
Measured: Change from Baseline at 28 weeks (T2)
Secondary outcomes (10)
Change of Stat Bend
Lateral trunk inclination in the upright standing position
Measured: Change from Baseline at 28 weeks (T2)
Change of Stat Flex
Anterior trunk flexion in the upright standing position
Measured: Change from Baseline at 28 weeks (T2)
Change of ROM Ips
Range of Motion (ROM) of trunk bending ipsilateral to the side of trunk deviation
Measured: Change from Baseline at 28 weeks (T2)
Change of ROM Con
Range of Motion (ROM) of trunk bending contralateral to the side of trunk deviation
Measured: Change from Baseline at 28 weeks (T2)
Change of ROM flex
Range of Motion (ROM) of anterior trunk flexion
Measured: Change from Baseline at 28 weeks (T2)
Change of ROM Ext
Range of Motion (ROM) of posterior trunk extension
Measured: Change from Baseline at 28 weeks (T2)
Change of Total ROM of the trunk
ROM Ips + ROM Con + ROM Flex + ROM Ext
Measured: Change from Baseline at 28 weeks (T2)
Change of The Unified Parkinson's Disease Rating Scale - part III - Motor examination (UPDRS-III)
It consists of 18 items (score from 0 to 4). Higher scores are worst otcomes.
Measured: Change from Baseline at 28 weeks (T2)
Change of Functional Independence Measure (FIM)
The Functional Independence Measure (FIM) is an 18-item measurement tool that explores an individual's physical, psychological and social function. FIM scores range from 1 to 7 (1= total assist and 7= complete independence).
Measured: Change from Baseline at 28 weeks (T2)
Change of Visual analog scale (VAS).
Lumbar pain severity was rated according to a 0 to 10 visual analog scale. Zero is no pain and 10 is worst pain.
Measured: Change from Baseline at 28 weeks (T2)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2020
- Study start15 Jan 2019
- Primary completion15 Aug 2020
- Study completion15 Sep 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (19)Papers the sponsor has linked to this study.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study was a randomized, double-blind, controlled trial
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Cristina Tassorelli, MD, Study director, IRCCS Mondino Foundation, Pavia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04620863
- Sponsor's protocol ID
- Pisa-tDCS
- Status last verified
- Oct 2020
- First submitted
- 26 Oct 2020
- Last updated
- 13 Nov 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol. 1972;202(2):94-103. doi: 10.1007/BF00316159. No abstract available.
PubMed 4115928Gambarin M, Antonini A, Moretto G, Bovi P, Romito S, Fiaschi A, Tinazzi M. Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report. Mov Disord. 2006 Feb;21(2):270-3. doi: 10.1002/mds.20711.
PubMed 16161148Barone P, Santangelo G, Amboni M, Pellecchia MT, Vitale C. Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment. Lancet Neurol. 2016 Sep;15(10):1063-74. doi: 10.1016/S1474-4422(16)30173-9. Epub 2016 Aug 8.
PubMed 27571158Tinazzi M, Gandolfi M, Ceravolo R, Capecci M, Andrenelli E, Ceravolo MG, Bonanni L, Onofrj M, Vitale M, Catalan M, Polverino P, Bertolotti C, Mazzucchi S, Giannoni S, Smania N, Tamburin S, Vacca L, Stocchi F, Radicati FG, Artusi CA, Zibetti M, Lopiano L, Fasano A, Geroin C. Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study. Mov Disord Clin Pract. 2019 Jun 29;6(7):576-585. doi: 10.1002/mdc3.12810. eCollection 2019 Sep.
PubMed 31538092Tinazzi M, Fasano A, Geroin C, Morgante F, Ceravolo R, Rossi S, Thomas A, Fabbrini G, Bentivoglio A, Tamma F, Cossu G, Modugno N, Zappia M, Volonte MA, Dallocchio C, Abbruzzese G, Pacchetti C, Marconi R, Defazio G, Canesi M, Cannas A, Pisani A, Mirandola R, Barone P, Vitale C; Italian Pisa Syndrome Study Group. Pisa syndrome in Parkinson disease: An observational multicenter Italian study. Neurology. 2015 Nov 17;85(20):1769-79. doi: 10.1212/WNL.0000000000002122. Epub 2015 Oct 21.
PubMed 26491088Tassorelli C, Furnari A, Buscone S, Alfonsi E, Pacchetti C, Zangaglia R, Pichiecchio A, Bastianello S, Lozza A, Allena M, Bolla M, Sandrini G, Nappi G, Martignoni E. Pisa syndrome in Parkinson's disease: clinical, electromyographic, and radiological characterization. Mov Disord. 2012 Feb;27(2):227-35. doi: 10.1002/mds.23930. Epub 2011 Oct 13.
PubMed 21997192Doherty KM, Davagnanam I, Molloy S, Silveira-Moriyama L, Lees AJ. Pisa syndrome in Parkinson's disease: a mobile or fixed deformity? J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1400-3. doi: 10.1136/jnnp-2012-304700. Epub 2013 Mar 26.
PubMed 23532719Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord. 2007 Oct 31;22(14):2097-103. doi: 10.1002/mds.21694.
PubMed 17685467Etoom M, Alwardat M, Aburub AS, Lena F, Fabbrizo R, Modugno N, Centonze D. Therapeutic interventions for Pisa syndrome in idiopathic Parkinson's disease. A Scoping Systematic Review. Clin Neurol Neurosurg. 2020 Nov;198:106242. doi: 10.1016/j.clineuro.2020.106242. Epub 2020 Sep 18.
PubMed 32979681Tinazzi M, Geroin C, Gandolfi M, Smania N, Tamburin S, Morgante F, Fasano A. Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management. Mov Disord. 2016 Dec;31(12):1785-1795. doi: 10.1002/mds.26829. Epub 2016 Oct 25.
PubMed 27779784Tassorelli C, De Icco R, Alfonsi E, Bartolo M, Serrao M, Avenali M, De Paoli I, Conte C, Pozzi NG, Bramanti P, Nappi G, Sandrini G. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord. 2014 Nov;20(11):1140-4. doi: 10.1016/j.parkreldis.2014.07.015. Epub 2014 Aug 13.
PubMed 25175601Castrioto A, Piscicelli C, Perennou D, Krack P, Debu B. The pathogenesis of Pisa syndrome in Parkinson's disease. Mov Disord. 2014 Aug;29(9):1100-7. doi: 10.1002/mds.25925. Epub 2014 Jun 7.
PubMed 24909134Di Matteo A, Fasano A, Squintani G, Ricciardi L, Bovi T, Fiaschi A, Barone P, Tinazzi M. Lateral trunk flexion in Parkinson's disease: EMG features disclose two different underlying pathophysiological mechanisms. J Neurol. 2011 May;258(5):740-5. doi: 10.1007/s00415-010-5822-y. Epub 2010 Nov 16.
PubMed 21079986Tinazzi M, Juergenson I, Squintani G, Vattemi G, Montemezzi S, Censi D, Barone P, Bovi T, Fasano A. Pisa syndrome in Parkinson's disease: an electrophysiological and imaging study. J Neurol. 2013 Aug;260(8):2138-48. doi: 10.1007/s00415-013-6945-8. Epub 2013 May 22.
PubMed 23695587Bartolo M, Serrao M, Tassorelli C, Don R, Ranavolo A, Draicchio F, Pacchetti C, Buscone S, Perrotta A, Furnari A, Bramanti P, Padua L, Pierelli F, Sandrini G. Four-week trunk-specific rehabilitation treatment improves lateral trunk flexion in Parkinson's disease. Mov Disord. 2010 Feb 15;25(3):325-31. doi: 10.1002/mds.23007.
PubMed 20131386
Study at a glance
From the registry record, last updated by the sponsor on 13 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE: A RANDOMIZED CONTROLLED TRIAL
- ClinicalTrials.gov ID
- NCT04620863
- Acronym / sponsor ID
- Pisa-tDCS
- Conditions
- Parkinson Disease, Pisa Syndrome
- Keywords
- Parkinson Disease, Pisa Syndrome, Transcranial direct current stimulation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- IRCCS National Neurological Institute "C. Mondino" FoundationUniversity, hospital or other
- Study start
- 15 Jan 2019 (actual)
- Primary completion
- 15 Aug 2020 (actual)
- Study completion
- 15 Sep 2020 (actual)
- First posted
- 9 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pisa Syndrome (PS) is a lateral trunk flexion frequently associated to Parkinson's disease (PD). The management of PS is still a challenge for the clinician, because it poorly responds to anti-parkinsonian drugs, and the improvement achieved with neurorehabilitation or botulinum toxin injections tends to fade in 6 months or less. Transcranial direct current stimulation (t-DCS) is a non-invasive neuromodulation technique, with promising results in movement disorders. Aim of our study is to evaluate the role of bi-hemispheric t-DCS as add-on to neurorehabilitation in PS. Twenty-eight patients affected by PD and PS were managed with a 4-week hospital neurorehabilitation programme and randomized to: 1) t-DCS group: 5 daily sessions (20 minutes - 2 mA) with cathode over the primary motor cortex (M1) contralateral to PS, and anode over the M1 cortex ipsilateral to PS; or 2) sham group. Patients were tested with kinematic analysis of trunk movement in static and dynamic conditions, UPDRS-III, FIM, and VAS for lumbar pain rating at hospital admission (T0), at hospital discharge (end of neurorehabilitation - T1), and 6 months later (T2). At T0, the evaluations were completed by an EMG study of trunk muscles activation.
Detailed description
Axial disorders are frequent complications of Parkinson's Disease (PD) and they can lead to postural deformities and balance impairments. The most prevalent postural disorders of PD are represented by camptocormia, antecollis, scoliosis, and Pisa syndrome (PS).
The pathogenesis of these disorders has not yet been completely elucidated, and it is characterized by a complex interlacement between central and peripheral mechanisms.
The first report of PS dates back in 1972, when Ekobm described a case series of three patients who developed a lateral trunk flexion in close temporal relationship with neuroleptics assumption. The roster of drugs associated with an acute/subacute onset of PS is huge and constantly growing, and it includes: antidepressants (mirtazapine, sertraline), cholinesterase inhibitor (rivastigmine, galantamine, donepezil), neuroleptics (tiapride, clotiapine, clozapine, aipiprazole, butyrophenone, paliperidone, quetiapine), dopamine agonists, (pramipexolo, ropinirole, pergolide), lithium, valproic acid, and betahistine. Nonetheless, PS was described as well in patients with neurodegenerative disorders, and in particular in PD and parkinsonism without drugs exposure.
The prevalence of PS is around 8.3% (9.3% in women and 6.4% in men) when calculated in a psychogeriatric population, and it is 8 to 8.8% when populations of PD patients were considered.
Formal diagnostic criteria for PS are not available, indeed the diagnosis is based on the clinical features:
- presence of a lateral flexion of the trunk with a homogenous angle between sacrum and spinous process of the 7th cervical vertebra;
- association of an ipsilateral rotation of the trunk around the sagittal axis that leads to a higher and anterior position of the shoulder contralateral to the side of trunk deviation;
- the postural disorder worsens during standing position, sitting position and gait;
- the postural disorder improves in supine position;
- disregard of patients for the postural disorder.
The fluctuation of the postural alteration during static (supine position vs. upright standing position) and dynamic conditions appears to be crucial to differentiate PS from scoliosis.
A lateral trunk deviation of at least 10° is commonly accepted for the diagnosis, although higher or lower cut-offs were used in the past. According to the degree of the lateral trunk flexion, PS can be further divided in mild (less than 20°) or severe (more than 20°) phenotypes.
Patients with PD and PS showed some typical clinical and demographic features when compared to PD patients without postural alterations: they are older, PD is longer in duration, more severe and with a more pronounced asymmetry of motor symptoms. The parkinsonian symptoms involving the upper limbs as well as gait impairment are more severe in PD patients with PS. Moreover, they are characterized by a higher incidence of falls, arthrosis, osteoporosis, orthopedics diseases and pain, specifically lumbar and lower back pain, which is reported in up to 75% of patients with PD and PS.
The management of PS is still a challenge for the physician. PS poorly responds to antiparkinsonian drugs, although there aren't studies specifically designed to assess this topic.
Neurorehabilitation represents one of the fundamental approach to PD and to postural disorders in general, not only for the treatment of the motor symptoms itself but also to improve quality of life and autonomy in the activity of daily living.
The study was a randomized, double-blind, controlled trial aimed to assess the efficacy of five daily sessions of bi-hemispheric t-DCS in add-on to an in-hospital neurorehabilitation protocol in patients affected by PD and PS.
At hospital admission (T0 - baseline), all patients underwent complete neurological, general and functional examinations by a Neurologist with expertise in movement disorders and neurorehabilitation. Patients who fulfilled inclusion and exclusion criteria underwent a baseline kinematic analysis of trunk movement. Patients with at least 10° of lateral trunk flexion completed the baseline evaluations with a dynamic electromyographic (EMG) study of trunk muscles, and with administration of a set clinical scales for the evaluations of motor disability, functional independence, and lumbar pain.
After that, patients were randomly assigned to "t-DCS" or "sham" treatment, and they started the double-blind phase of the study. The 5-day t-DCS/sham treatment was delivered in 5 daily consecutive sessions, starting from the first Monday after hospital admission. In parallel to neuromodulation, all patients were treated with a standardized 4-week rehabilitation programme. The kinematic analysis of trunk movement as well as the administration of the set of questionnaires were repeated at the end of the 4-week rehabilitation programme (T1 - hospital discharge), and 6 months after discharge (T2).
The randomization was performed according to a block randomization method. A unique randomization list was generated before enrollment with the following parameters: 6 blocks; 6 patients per block (3 for t-DCS group, and 3 for sham group).
All the patients were treated with an optimized and individualized anti-parkinsonian therapy, which dose and regimen were kept stable during the overall study period. All the evaluations were performed in the morning, and always in an ON phase.
The specific and standardized in-hospital rehabilitation programme was focused on the rehabilitation of the trunk postural disorder. All patients were treated with 90-minute daily sessions, 6 days a week (Monday to Saturday) for four weeks.
Each session was structured as follow:
- 10 minutes of cardiovascular warm-up activities: intersegmental coordination exercises; exercises to release shoulder and pelvic girdle; pelvic anteversion and retroversion movements to improve diaphragmatic respiration (supine position); breathing exercises to promote expansion of the chest;
- 15 minutes of stretching exercises: exercises to stretch the muscles of the posterior kinematic chain; exercises to stretch the pectoralis muscles; exercises to stretch the ischio-cruralis muscles; assumption of the prone position, sitting on heels and stretching the arms out in front; the "bridge" exercise to stretch the muscles of the anterior abdominal wall, glutei, quadriceps and hamstring; exercises to stretch lumbar muscles (in the supine position, each knee, in turn, is brought to the chest);
- 15 minutes of strengthening exercises in a functional context: exercises to strengthen the dorsal muscles (arms extended and hands outstretched as though to take something); lateral bending (arms lying along the body and hands reaching down as though to pick up something); stretching using the wall bars;
- 20 minutes of gait training: overground gait training (forwards, backwards, and lateral); walking on the spot;
- 15 minutes of balance training: path with obstacles; balance exercises performed in order of difficulty (heel-to-toe walking, lateral walking crossing the legs, walking along a path on surfaces of different texture);
- 15 minutes of relaxation exercises: intersegmental coordination exercises; segmental passive mobilization (until maximum joint range of motion is reached); breathing exercises to promote expansion of the chest.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- The study was a randomized, double-blind, controlled trial
| Arm | Type | Receives |
|---|---|---|
| tDCS group | Experimental | Other: t-DCS groupPatients randomized to the experimental group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity delivered at anodal and cathodal levels. |
| Sham Group | Sham comparator | Other: Sham groupThe stimulation setting was exactly the same of the experimental group but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- age between 18 and 80 years;
- Hoehn and Yahr stage between II and III;
- Mini-Mental State Examination score above 24;
- lateral trunk flexion of at least 10° at baseline.
Key exclusion criteria (10 listed)
- history of major psychiatric or other neurological conditions;
- history of back surgery, tumors or infections of the spine, intradural or extradural hematoma, ankylosing spondylitis, spinal stenosis;
- history of idiopathic scoliosis;
- botulin toxin treatment in the previous year;
- any change in dose or regimen of the anti-parkinsonian therapy in the last month before enrolment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| t-DCS groupAll the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation). | Other | tDCS group |
| Sham groupThe stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation. | Other | Sham Group |
Primary outcome
Change of Stat Tot (Stat Bend + Stat Flex)
Time frame: Change from Baseline at 28 weeks (T2)
Total postural alteration in the upright standing position (Stat Tot): lateral trunk inclination in the upright standing position (Stat Bend) plus anterior trunk flexion in the upright standing position (Stat Flex).
10 secondary outcomes
Change of Stat Bend
Time frame: Change from Baseline at 28 weeks (T2)
Change of Stat Flex
Time frame: Change from Baseline at 28 weeks (T2)
Change of ROM Ips
Time frame: Change from Baseline at 28 weeks (T2)
Change of ROM Con
Time frame: Change from Baseline at 28 weeks (T2)
Change of ROM flex
Time frame: Change from Baseline at 28 weeks (T2)
Change of ROM Ext
Time frame: Change from Baseline at 28 weeks (T2)
Change of Total ROM of the trunk
Time frame: Change from Baseline at 28 weeks (T2)
Change of The Unified Parkinson's Disease Rating Scale - part III - Motor examination (UPDRS-III)
Time frame: Change from Baseline at 28 weeks (T2)
Change of Functional Independence Measure (FIM)
Time frame: Change from Baseline at 28 weeks (T2)
Change of Visual analog scale (VAS).
Time frame: Change from Baseline at 28 weeks (T2)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Nov 2020.
- Background: PubMed 4115928Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol. 1972;202(2):94-103. doi: 10.1007/BF00316159. No abstract available.
- Background: PubMed 16161148Gambarin M, Antonini A, Moretto G, Bovi P, Romito S, Fiaschi A, Tinazzi M. Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report. Mov Disord. 2006 Feb;21(2):270-3. doi: 10.1002/mds.20711.
- Background: PubMed 27571158Barone P, Santangelo G, Amboni M, Pellecchia MT, Vitale C. Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment. Lancet Neurol. 2016 Sep;15(10):1063-74. doi: 10.1016/S1474-4422(16)30173-9. Epub 2016 Aug 8.
- Background: PubMed 31538092Tinazzi M, Gandolfi M, Ceravolo R, Capecci M, Andrenelli E, Ceravolo MG, Bonanni L, Onofrj M, Vitale M, Catalan M, Polverino P, Bertolotti C, Mazzucchi S, Giannoni S, Smania N, Tamburin S, Vacca L, Stocchi F, Radicati FG, Artusi CA, Zibetti M, Lopiano L, Fasano A, Geroin C. Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study. Mov Disord Clin Pract. 2019 Jun 29;6(7):576-585. doi: 10.1002/mdc3.12810. eCollection 2019 Sep.
- Background: PubMed 26491088Tinazzi M, Fasano A, Geroin C, Morgante F, Ceravolo R, Rossi S, Thomas A, Fabbrini G, Bentivoglio A, Tamma F, Cossu G, Modugno N, Zappia M, Volonte MA, Dallocchio C, Abbruzzese G, Pacchetti C, Marconi R, Defazio G, Canesi M, Cannas A, Pisani A, Mirandola R, Barone P, Vitale C; Italian Pisa Syndrome Study Group. Pisa syndrome in Parkinson disease: An observational multicenter Italian study. Neurology. 2015 Nov 17;85(20):1769-79. doi: 10.1212/WNL.0000000000002122. Epub 2015 Oct 21.
- Background: PubMed 21997192Tassorelli C, Furnari A, Buscone S, Alfonsi E, Pacchetti C, Zangaglia R, Pichiecchio A, Bastianello S, Lozza A, Allena M, Bolla M, Sandrini G, Nappi G, Martignoni E. Pisa syndrome in Parkinson's disease: clinical, electromyographic, and radiological characterization. Mov Disord. 2012 Feb;27(2):227-35. doi: 10.1002/mds.23930. Epub 2011 Oct 13.
- Background: PubMed 23532719Doherty KM, Davagnanam I, Molloy S, Silveira-Moriyama L, Lees AJ. Pisa syndrome in Parkinson's disease: a mobile or fixed deformity? J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1400-3. doi: 10.1136/jnnp-2012-304700. Epub 2013 Mar 26.
- Background: PubMed 17685467Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord. 2007 Oct 31;22(14):2097-103. doi: 10.1002/mds.21694.
- Background: PubMed 32979681Etoom M, Alwardat M, Aburub AS, Lena F, Fabbrizo R, Modugno N, Centonze D. Therapeutic interventions for Pisa syndrome in idiopathic Parkinson's disease. A Scoping Systematic Review. Clin Neurol Neurosurg. 2020 Nov;198:106242. doi: 10.1016/j.clineuro.2020.106242. Epub 2020 Sep 18.
- Background: PubMed 27779784Tinazzi M, Geroin C, Gandolfi M, Smania N, Tamburin S, Morgante F, Fasano A. Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management. Mov Disord. 2016 Dec;31(12):1785-1795. doi: 10.1002/mds.26829. Epub 2016 Oct 25.
- Background: PubMed 25175601Tassorelli C, De Icco R, Alfonsi E, Bartolo M, Serrao M, Avenali M, De Paoli I, Conte C, Pozzi NG, Bramanti P, Nappi G, Sandrini G. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord. 2014 Nov;20(11):1140-4. doi: 10.1016/j.parkreldis.2014.07.015. Epub 2014 Aug 13.
- Background: PubMed 24909134Castrioto A, Piscicelli C, Perennou D, Krack P, Debu B. The pathogenesis of Pisa syndrome in Parkinson's disease. Mov Disord. 2014 Aug;29(9):1100-7. doi: 10.1002/mds.25925. Epub 2014 Jun 7.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Recruiting
Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in Parkinson Disease
Parkinson's Disease (PD)
Active, not recruitingPhase 2
A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease
Parkinson&Amp;#39;s Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Not yet recruiting
Cognitive-Motor Training for Gait Adaptability in Parkinson Disease
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cristina Tassorelli, MD study director
IRCCS Mondino Foundation, Pavia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing t-DCS group in people with Parkinson Disease and Pisa Syndrome, run by IRCCS National Neurological Institute "C. Mondino" Foundation at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of Stat Tot (Stat Bend + Stat Flex) (time frame: Change from Baseline at 28 weeks (T2)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04620863, which also lists 19 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Nov 2020.